Antibodies main page header.jpg
Antibodies main page header thumbnail.jpg

Antibody Manufacturing


Experts in Antibody production

We offer in vitro cell culture production of monoclonal antibody in roller bottles. Our cGMP facility can accommodate 1L to 100L volumes generating milligram to gram quantities of antibody. Cell lines can be produced in our standard hybridoma media or in custom media formulations provided by the customer.

Media formulations containing low IgG fetal bovine serum, serum-free media, or animal component-free media can be used for productions when more stringent requirements are necessary. Productions are designed to limit the introduction of endotoxin.

Monoclonal antibody produced in roller bottles is typically concentrated and purified prior to shipment.

The BBI Difference

Choice & Flexibility

Choice & Flexibility

Our core competencies include a comprehensive suite of reagents with custom development options, lateral flow development, diagnostic manufacturing services and smartphone reader technologies.

Quality System Certification

Quality System Certification

Each site follows strict Quality Control and product release protocols, which coupled with effective Quality Assurance processes ensure our products meet stringent product quality, safety and customer requirements.



Innovation is at the heart of our operations. The extensive breadth and depth of our products and services portfolio is testimony to the ongoing investment in our people and facilities.

Experience & Trust

Experience & Trust

BBI Solutions has been serving the global diagnostics industry for over 50 years and is the world’s largest independent producer of immuno-diagnostics reagents.

BBI Solutions Brands


The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.


Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.


Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox